The Q4 2026 PMDA submission is the primary catalyst. Monitor for partnership announcements around the Helix/Heart3D delivery platform and allogeneic MSC pipeline, which could provide non-dilutive funding.
Price Chart
Executive Summary
BioCardia issued a shareholder letter following a recent capital raise, outlining key 2026 milestones: a planned Q4 2026 submission to Japan's PMDA for CardiAMP Cell Therapy approval (targeting 20,000-patient subgroup with $124,000/procedure reimbursement precedent), ongoing US CardiAMP HF II trial enrollment, and pipeline partnership discussions. The filing is a forward-looking update with no new financial results; the company notes modest cash burn and that the recent financing should fund the PMDA submission and trial enrollment.
Key Facts
- BioCardia completed a 'clean financing' capital raise in the week prior to this filing
- Plans to submit CardiAMP Cell Therapy to Japan PMDA for approval by end of Q4 2026
- Japan PMDA has indicated support for potential approval of CardiAMP for ischemic HFrEF
- Estimated 300,000 patients in Japan with ischemic heart failure; initial approval targets 20,000-patient subgroup
- Prior cardiac cell therapies in Japan had reimbursement at $124,000 per procedure
- Four active US study centers for CardiAMP HF II trial; working to onboard additional centers
- Japan is a trusted Reference Country and MDSAP member, enabling expedited approvals in other regions
- Company has two FDA-approved INDs for allogeneic MSC therapies targeting cardiac and pulmonary indications
- Revised SEC regulations expected later this year may ease capital access for smaller reporting companies
Financial Impact
No financial results reported. The recent capital raise (undisclosed amount) is intended to fund PMDA submission and trial enrollment. Prior reimbursement precedent of $124,000/procedure noted for context.
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; regulatory and clinical execution risk
- Dependence on successful PMDA submission and subsequent approval for value inflection
- Limited cash runway despite 'modest' burn; may require additional capital before revenue generation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| 8-K Filing (BCDA) — Batch item 1 | 0001437749-26-021041 |
| Exhibit: ex_978573.htm | 0001437749-26-021041 |
| Document: 0001437749-26-021041-index-headers.html | press-3314112 |
| Document: 0001437749-26-021041-index.html | press-3314112 |
| Document: 0001437749-26-021041.txt | press-3314112 |
| PRESS-RELEASE Data (Synthetic) | press-3314112 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers